I kappa B KINASES

Abstract: The invention provides methods and compositions relating to I kappa B regulating proteins, known as T2K proteins, and related nucleic acids. The proteins may be produced recombinantly from transformed host cells from the disclosed T2K encoding nucleic acid or purified from human cells. The invention provides specific hybridization probes and primers capable of specifically hybridizing with the disclosed T2K gene, T2K-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.

Description: IκB Kinases INTRODUCTION Field of the Invention The field of this invention is a family of kinases which regulate signal transduction. Background Inflammatory cytokines IL-1 and TNF exert diverse biological activities by altering gene expression in the cells, a function mediated mostly by transcription factor NF-κB. In unstimulated cells, NF-κB proteins form a complex with inhibitory molecules, the IκB proteins, and are rendered inactive in the cytoplasm. In response to cytokines and other stimuli, the IκB proteins are phosphorylated on specific serine residues. In particular, phosphorylation of two serine residues as part of the consensus sequence DSGLJLXSM/L (e.g. ser 32 and 36 in IκBα, ser 19 and 23 in IκBβ, and ser 157 and 161, or 18 and 22, depending on the usage of methionines, in IκBe, respectively) which mark the proteins for ubiquitination and proteosome-mediated degradation, releasing NF-κB to enter the nucleus to activate the genes that encode proteins participating in inflammatory and immune responses. Henceforth, the term IκB serine 36 is used herein to refer generically to the second serine residue of the foregoing consensus sequence, e.g. that corresponding to serine 36 in IκBα, ser 23 in IκBβ, and ser 161 or 22 in IκBe. Delineating TNF and IL-1 signaling pathways for NF-κB activation has implicated the TRAF molecules as converging point for different cytokines, with TRAF2 being involved in TNF- and TRAF6 in IL-1-induced NF-κB activation. We disclose herein a family of IκB kinases including a TRAF2-associated kinase activity (designated T2K) and the translation product of the KIAA0151 gene product that phosphorylates the IκB molecules on the specific regulatory serine residues. We also disclose the purification of a native protein responsible for such kinase activity, the sequencing of T2K peptides derived, and the cloning of native T2K cDNA. Relevant Literature Nagase et al. (1995) DNA Res. 2(4), 167-174 report conceptual coding sequences from a number of unidentified human genes including KIAA0151. Song et al., US Patent Application Serial No. 08/677,862 discloses a TRAF2-associated kinase. SUMMARY OF THE INVENTION The invention provides methods and compositions relating to natural isolated regulatory proteins called T2K proteins, related nucleic acids, and protein domains thereof having T2K-specific activity. The proteins may be produced recombinantly from transformed host cells from the subject T2K encoding nucleic acids or purified from mammalian cells. The invention provides isolated T2K hybridization probes and primers capable of specifically hybridizing with the disclosed T2K gene, T2K-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis (e.g. genetic hybridization screens for T2K transcripts), therapy (e.g. gene therapy to modulate T2K gene expression) and in the biopharmaceutical industry (e.g. as immunogens, reagents for isolating other transcriptional regulators, reagents for screening chemical libraries for lead pharmacological agents , etc . ) . DETAILED DESCRIPTION OF THE INVENTION The nucleotide sequences of a natural cDNA encoding a human T2K protein is shown as SEQ LD NO: 1, and the full conceptual translate is shown as SEQ ID NO:2. The T2K proteins of the invention include incomplete translates of SEQ ID NO: 1 and deletion mutants of SEQ ID NO:2, which translates and deletion mutants have T2K-specific amino acid sequence and assay-discernable T2K-specific binding specificity or function. Such active T2K deletion mutants, T2K peptides or protein domains comprise a sequence of at least about 6, preferably at least about 8, more preferably at least about 10 consecutive residues of SEQ ID NO:2 which distinguishes both the KLAA0151 gene product and the translation product of SEQ ID NO:l, bases 1756-2095. For examples, T2K protein domains identified below are shown to provide protein-binding domains which are identified in and find use, inter alia, in solid-phase binding and kinase assays as described below. T2K-specific activity or function may be determined by convenient in vitro, cell- based, or in vivo assays: e.g. in vitro binding assays, cell culture assays, in animals (e.g. gene therapy, transgenics, etc.), etc. Binding assays encompass any assay where the molecular interaction of an T2K protein with a binding target is evaluated. The binding target may be a natural intracellular binding target (including substrates, agonists and antagonists) such as an IκB or TRAF2, or other regulator that directly modulates T2K activity or its localization; or non-natural binding target such a specific immune protein such as an antibody, or an T2K specific agent such as those identified in screening assays such as described below. T2K- binding specificity may assayed by binding equilibrium constants (usually at least about 10 7 M "1 , preferably at least about 10 8 M "1 , more preferably at least about 10 9 M "1 ), by the ability of the subject protein to function as negative mutants in T2K-expressing cells, to elicit T2K specific antibody in a heterologous host (e.g a rodent or rabbit), etc.; or, in a preferred embodiment, by kinase activity. The claimed T2K proteins are isolated or pure: an "isolated" protein is unaccompanied by at least some of the material with which it is associated in its natural state, preferably constituting at least about 0.5%, and more preferably at least about 5% by weight of the total protein in a given sample and a pure protein constitutes at least about 90%, and preferably at least about 99% by weight of the total protein in a given sample. The T2K proteins and protein domains may be synthesized, produced by recombinant technology, or purified from mammalian, preferably human cells. A wide variety of molecular and biochemical methods are available for biochemical synthesis, molecular expression and purification of the subject compositions, see e.g. Molecular Cloning, A Laboratory Manual (Sambrook, et al. Cold Spring Harbor Laboratory), Current Protocols in Molecular Biology (Eds. Ausubel, et al, Greene Publ. Assoc, Wiley-Interscience, NY) or that are otherwise known in the art. The invention provides natural and non-natural T2K-specific binding agents, methods of identifying and making such agents, and their use in diagnosis, therapy and pharmaceutical development. For example, T2K-specific agents are useful in a variety of diagnostic and therapeutic applications. Novel T2K-specific binding agents include T2K-specific receptors, such as somatically recombined protein receptors like specific antibodies or T-cell antigen receptors (see, e.g Harlow and Lane (1988) Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory) and other natural intracellular binding agents identified with assays such as one-, two- and three-hybrid screens, non-natural intracellular binding agents identified in screens of chemical libraries such as described below, etc. For diagnostic uses, the binding agents are frequently labeled, such as with fluorescent, radioactive, chemiluminescent, or other easily detectable molecules, either conjugated directly to the binding agent or conjugated to a probe specific for the binding agent. Agents of particular interest modulate T2K function, e.g. T2K kinase activity; for example, isolated cells, whole tissues, or individuals may be treated with a T2K binding agent to activate, inhibit, or alter T2K-kinase dependent processes such as Nfi B activation. The amino acid sequences of the disclosed T2K proteins are used to back-translate T2K protein-encoding nucleic acids optimized for selected expression systems (Holler et al. (1993) Gene 136, 323-328; Martin et al. (1995) Gene 154, 150-166) or used to generate degenerate oligonucleotide primers and probes for use in the isolation of natural T2K- encoding nucleic acid sequences ("GCG" software, Genetics Computer Group, Inc, Madison WI). T2K-encoding nucleic acids used in T2K-expression vectors and incorporated into recombinant host cells, e.g. for expression and screening, transgenic animals, e.g. for functional studies such as the efficacy of candidate drugs for disease associated with T2K- modulated cell function, etc. The invention also provides nucleic acid hybridization probes and replication / amplification primers having a hitherto novel T2K cDNA specific sequence contained in SEQ ID NO: 1 (including its complement and analogs and complements thereof having the corresponding sequence, e.g . in RNA) and sufficient to effect specific hybridization thereto (i.e. specifically hybridize with SEQ ID NO: 1 in the presence of the KIAA0151 gene and nucleic acids consisting of SEQ ID NO:l, bases 1756-2095). Such primers or probes are at least 12, preferably at least 24, more preferably at least 36 and most preferably at least 96 bases in length. Demonstrating specific hybridization generally requires stringent conditions, for example, hybridizing in a buffer comprising 30% formamide in 5 x SSPE (0.18 M NaCl, 0.01 M NaPO 4 , pH7.7, 0.001 M EDTA) buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2 x SSPE; preferably hybridizing in a buffer comprising 50% formamide in 5 x SSPE buffer at a temperature of 42°C and remaining bound when subject to washing at 42°C with 0.2 x SSPE buffer at 42°C. T2K cDNA homologs can also be distinguished from other protein using alignment algorithms, such as BLASTX (Altschul et al. (1990) Basic Local Alignment Search Tool, J Mol Biol 215, 403- 410). The subject nucleic acids are of synthetic/non-natural sequences and/or are isolated, i.e. unaccompanied by at least some of the material with which it is associated in its natural state, preferably constituting at least about 0.5%, preferably at least about 5% by weight of total nucleic acid present in a given fraction, and usually recombinant, meaning they comprise a non-natural sequence or a natural sequence joined to nucleotide(s) other than that which it is joined to on a natural chromosome. Nucleic acids comprising the nucleotide sequence of SEQ LD NO: 1 or fragments thereof, contain such sequence or fragment at a terminus, immediately flanked by a sequence other than that which it is joined to on a natural chromosome, or flanked by a native flanking region fewer than 10 kb, preferably fewer than 2 kb, which is at a terminus or is immediately flanked by a sequence other than that which it is joined to on a natural chromosome. While the nucleic acids are usually RNA or DNA, it is often advantageous to use nucleic acids comprising other bases or nucleotide analogs to provide modified stability, etc. The subject nucleic acids find a wide variety of applications including use as translatable transcripts, hybridization probes, PCR primers, diagnostic nucleic acids, etc.; use in detecting the presence of T2K genes and gene transcripts and in detecting or amplifying nucleic acids encoding additional T2K homologs and structural analogs. In diagnosis, T2K hybridization probes find use in identifying wild-type and mutant T2K alleles in clinical and laboratory samples. Mutant alleles are used to generate allele-specific oligonucleotide (ASO) probes for high-throughput clinical diagnoses. In therapy, therapeutic T2K nucleic acids are used to modulate cellular expression or intracellular concentration or availability of active T2K. For example, T2K nucleic acids are also used to modulate cellular expression or intracellular concentration or availability of active T2K protein. T2K inhibitory nucleic acids are typically antisense: single-stranded sequences comprising complements of the disclosed natural T2K coding sequences. Antisense modulation of the expression of a given T2K protein may employ antisense nucleic acids operably linked to gene regulatory sequences. Cell are transfected with a vector comprising a T2K sequence with a promoter sequence oriented such that transcription of the gene yields an antisense transcript capable of binding to endogenous T2K encoding mRNA. Transcription of the antisense nucleic acid may be constitutive or inducible and the vector may provide for stable extrachromosomal maintenance or integration. Alternatively, single-stranded antisense nucleic acids that bind to genomic DNA or mRNA encoding a given T2K protein may be administered to the target cell, in or temporarily isolated from a host, at a concentration that results in a substantial reduction in expression of the targeted protein. An enhancement in T2K expression is effected by introducing into the targeted cell type T2K nucleic acids which increase the functional expression of the corresponding gene products. Such nucleic acids may be T2K expression vectors, vectors which upregulate the functional expression of an endogenous allele, or replacement vectors for targeted correction of mutant alleles. Techniques for introducing the nucleic acids into viable cells are known in the art and include retroviral- based transfection, viral coat protein-liposome mediated transfection, etc. The invention provides efficient methods of identifying agents, compounds or lead compounds for agents active at the level of an IκB serine 36 specific kinase protein modulatable cellular function. Generally, these screening methods involve assaying for compounds which modulate IκB serine 36 specific kinase protein interaction with a natural IκB serine 36 specific kinase protein binding target. A wide variety of assays for binding agents are provided including labeled in vitro protein-protein binding assays, immunoassays, cell based assays, etc. The methods are amenable to automated, cost-effective high throughput screening of chemical libraries for lead compounds. Such libraries encompass candidate agents of encompass numerous chemical classes, though typically they are organic compounds; preferably small organic compounds and are obtained from a wide variety of sources including libraries of synthetic or natural compounds. Identified agents find use in the pharmaceutical industries for animal and human trials; for example, the agents may be derivatized and rescreened in in vitro and in vivo assays to optimize activity and minimize toxicity for pharmaceutical development. In vitro binding assays employ a mixture of components including a IκB serine 36 specific kinase protein such as a T2K protein, which may be part of a fusion product with another peptide or polypeptide, e.g. a tag for detection or anchoring, etc. The assay mixtures comprise a natural intracellular binding target of the kinase protein. While native binding targets may be used, it is frequently preferred to use portions (e.g. peptides) thereof so long as the portion provides binding affinity and avidity to the subject kinase protein conveniently measurable in the assay. In a particular embodiment, the binding target is a substrate comprising IκB serine 36. Such substrates comprise a IκBα, β or e peptide including the serine 36 residue and at least 5, preferably at least 10, and more preferably at least 20 naturally occuring immediately flanking residues on each side (i.e. residues 26-46, 22-42, or 12-32 or 151-171 for IκBα, β or e -derived substrates, respectively). The assay mixture also comprises a candidate pharmacological agent and typically, a variety of other reagents such as salts, buffers, neutral proteins, e.g. albumin, detergents, protease inhibitors, nuclease inhibitors, antimicrobial agents, etc. The mixture components can be added in any order that provides for the requisite bindings and incubations may be performed at any temperature which facilitates optimal binding. The mixture is then incubated under conditions whereby, but for the presence of the candidate pharmacological agent, the kinase protein specifically binds the cellular binding target, portion or analog with a reference binding affinity. Incubation periods are likewise selected for optimal binding but also minimized to facilitate rapid, high-throughput screening. After incubation, the agent-biased binding between the kinase protein and one or more binding targets is detected by any convenient way. First, a separation step is generally used to separate bound from unbound components. Separation may be effected by precipitation (e.g. TCA precipitation, immunoprecipitation, etc.), immobilization (e.g on a solid substrate), etc., followed by washing by, for examples, membrane filtration, gel chromatography (e.g. gel filtration, affinity, etc.). One of the components usually comprises or is coupled to a label. The label may provide for direct detection as radioactivity, luminescence, optical or electron density, etc. or indirect detection such as an epitope tag, an enzyme, etc. A variety of methods may be used to detect the label depending on the nature of the label and other assay components, e.g. through optical or electron density, radiative emissions, nonradiative energy transfers, etc. or indirectly detected with antibody conjugates, etc. A difference in the binding affinity of the kinase protein to the target in the absence of the agent as compared with the binding affinity in the presence of the agent indicates that the agent modulates the binding of the kinase protein to the binding target. Analogously, in the cell-based transcription assay also described below, a difference in the kinase protein transcriptional induction in the presence and absence of an agent indicates the agent modulates kinase-modulated transcription. A difference, as used herein, is statistically significant and preferably represents at least a 50%, more preferably at least a 90% difference. The following experimental section and examples are offered by way of illustration and not by way of limitation. EXPERIMENTAL Identification ofT2K: 293 cells were stably transfected with DNA plasmids that direct the expression of the human TRAF2 protein with an N-terminal Flag-epitope tag. Cells grown in suspension culture were pelleted in 500 ml bottles in a Sorvall GS-3 rotor spun at 2000 RPM for 5 minutes and were lysed in 5 pelleted-cell-volumes of "lysis buffer" containing 50 mM Hepes, pH 7.9, 250 mM NaCl, 5 mM dithiothreitol (DTT), 1 mM EDTA, 20 mM β glycerophosphate, 5 mM p-nitrophenyl phosphate, 1 mM Na orthovanadate, 1 mM benzamidine, 0.4 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM Na metabisulfite, 0.1% NP-40 and 10% (v/v) glycerol. After incubation on ice for 30 minutes with occasional rocking, cell lysate was centrifuged in a 50 ml conical tube in a Sorvall H6000A rotor at 4000 RPM for 10 minutes. Supernatants were collected and centrifuged in a Beckman 45 TI rotor at 40,000 RPM for 2 hours. The TRAP complex was immunoprecipitated using anti-flag monoclonal antibodies cross-linked to sepharose (NVVR) (1.5 ml sepharose beads for 200 mis of extracts). The immunoprecipitates were washed 4 times with cell lysis buffer, twice with lysis buffer containing 1 molar ΝaCl, then twice with lysis buffer. At this stage, the immunocomplex can efficiently phosphorylate wild type IκBα and β but not the mutants with the two serines substituted with alanines. The sepharose beads containing TRAF2 complex were then incubated at 30 °C for 1 hour in 4.5 mis of kinase buffer containing 20 mM Tris-HCl, pH 7.6, 20 mM MgCl 2 , 20 mM β glycerophosphate, 20 mM p-nitrophenyl phosphate, 1 mM EDTA, 1 mM Νa orthovanadate, 1 mM benzamidine, 0.4 mM PMSF, 1 mM Νa metabisulfite, 1 mM ATP, and 20 mM creatinephosphate. After the in vitro kinase reaction, significant amounts of the IκB kinase activity were found in the soluble fraction which was loaded on an 1 ml heparin agarose column and eluted with a ΝaCl gradient. The IκB kinase activity was recovered in the flow though fraction which was concentrated with a centricon (Amicon) to 50 ul. The material was fractionated on a superdex 200 gel filtration column driven by the Smart system (Pharmacia) and the eluate was collected in 50 ul fractions. The kinase activity was recovered in the fractions that correlated with molecule size marker of 670 kD. These fractions were pooled and further separated on a Mono Q column by a ΝaCl linear gradient. The kinase activity was found in 0.3 to 0.4 M ΝaCl eluate. Silver staining of the column fractions separated on SDS gels revealed an 85 to 90 kD polypeptide that correlated with the kinase activity in both superdex 200 and Mono Q fractionation. After SDS gel separation, this polypeptide was subjected to micropeptide sequencing. One peptide sequence obtained matched a partial cDΝA sequence in the Merck-Washington University Est database. A cDΝA clone that contains open reading frame for 729 amino acids was isolated from a lambda phage cDΝA library generated from HeLa cells. Sequence analysis revealed a protein kinase domain in the Ν-terminal portion of the predicted protein (T2K). Searching protein sequence database with the kinase domain of T2K identified a protein (KIAA0151) highly homologous to T2K, specially in the protein kinase domain (75% identity). KIAA0151 is a kinase with undefined function and was reported by Nagase T. et al. as a novel cDNA sequence isolated from human KG-1 cells (DNA Res. 2 (4), 167-174 (1995). Substrate specificity analysis revealed that both T2K and KLAA0151 specifically phosphorylate IκB serine 36 and associate with TRAF2. Furthermore, deletion mutant analysis reveals that residues 10-250 define kinase domains and residues 251-729 and 251-716, for T2K and KIAA0151 respectively, define regulatory domains active as a negative mutants for IκB kinase activity. Recombinant T2K kinase is prepared by over-expressing GST fusion proteins in E. coli and baculavirus expression systems. EXAMPLES 1. Protocol for at T2K - IκB phosphorylation assay. A. Reagents: - Neutralite Avidin: 20 μg/ml in PBS. - kinase: 10 "8 - 10 "5 M kinase (SEQ ID NO:2) at 20 μg/ml in PBS. - substrate: 10 "7 - lO^M biotinylated substrate (21 residue peptide consisting of residues 26-46 of human IκBα) at 40 μg/ml in PBS. - Blocking buffer: 5% BSA, 0.5% Tween 20 in PBS; 1 hour at room temperature. - Assay Buffer: 100 mM KC1, 10 mM MgCl 2 , 1 mM MnCl 2 , 20 mM HEPES pH 7.4, 0.25 mM EDTA, 1% glycerol, 0.5% NP-40, 50 mM BME, 1 mg/ml BSA, cocktail of protease inhibitors. -r 32 Plγ-ATP lOx stock: 2 x 10 "5 M cold ATP with 100 μCi [ 32 P]γ-ATP. Place in the 4°C microfridge during screening. - Protease inhibitor cocktail (1000X): 10 mg Trypsin Inhibitor (BMB # 109894), 10 mg Aprotinin (BMB # 236624), 25 mg Benzamidine (Sigma # B-6506), 25 mg Leupeptin (BMB # 1017128), 10 mg APMSF (BMB # 917575), and 2mM NaVo 3 (Sigma # S-6508) in 10 ml of PBS. B. Preparation of assay plates: - Coat with 120 μl of stock N Avidin per well overnight at 4°C. - Wash 2 times with 200 μl PBS. - Block with 150 μl of blocking buffer. - Wash 2 times with 200 μl PBS. C. Assay: - Add 40 μl assay buffer/well. - Add 40 μl biotinylated substrate (2-200 pmoles/40 ul in assay buffer) - Add 40 μl kinase (0.1-10 pmoles/40 ul in assay buffer) - Add 10 μl compound or extract. - Add 10 μl [ 32 P]γ-ATP lOx stock. - Shake at 25 °C for 15 minutes. - Incubate additional 45 minutes at 25 °C. - Stop the reaction by washing 4 times with 200 μl PBS. - Add 150 μl scintillation cocktail. - Count in Topcount. D. Controls for all assays (located on each plate): a. Non-specific binding b. cold ATP at 80% inhibition. 2. Protocol for at KLAA0151 - IκBβ phosphorylation assay. A. Reagents: - Neutralite Avidin: 20 μg/ml in PBS. - kinase: 10 "8 - 10 "5 M truncated KIAA0151 kinase (residues 4-714) at 20 μg/ml in PBS. - substrate: 10 "7 - lO^M biotinylated substrate (21 residue peptide consisting of residues 22-42 of human IκBβ) at 40 μg/ml in PBS. - Blocking buffer: 5% BSA, 0.5% Tween 20 in PBS; 1 hour at room temperature. - Assay Buffer: 100 mM KC1, 10 mM MgCl 2 , 1 mM MnCl 2 , 20 mM HEPES pH 7.4, 0.25 mM EDTA, 1% glycerol, 0.5% NP-40, 50 mM BME, 1 mg/ml BSA, cocktail of protease inhibitors. -r 32 P1γ-ATP lOx stock: 2 x 10 5 M cold ATP with 100 μCi [ 32 P]γ-ATP. Place in the 4°C microfridge during screening. - Protease inhibitor cocktail (1000X): 10 mg Trypsin inhibitor (BMB # 109894), 10 mg Aprotinin (BMB # 236624), 25 mg Benzamidine (Sigma # B-6506), 25 mg Leupeptin (BMB # 1017128), 10 mg APMSF (BMB # 917575), and 2mM NaVo 3 (Sigma # S-6508) in 10 ml of PBS. B. Preparation of assay plates: - Coat with 120 μl of stock N Avidin per well overnight at 4°C. - Wash 2 times with 200 μl PBS. - Block with 150 μl of blocking buffer. - Wash 2 times with 200 μl PBS. C. Assay: - Add 40 μl assay buffer/well. - Add 40 μl biotinylated substrate (2-200 pmoles/40 ul in assay buffer) - Add 40 μl kinase (0.1-10 pmoles/40 ul in assay buffer) - Add 10 μl compound or extract. - Add 10 μl [ 32 P]γ-ATP lOx stock. - Shake at 25 °C for 15 minutes. - Incubate additional 45 minutes at 25 °C. - Stop the reaction by washing 4 times with 200 μl PBS. - Add 150 μl scintillation cocktail. - Count in Topcount. D. Controls for all assays (located on each plate): a. Non-specific binding b. cold ATP at 80% inhibition. 3. Protocol for high throughput T2K-TRAF2 heterodimer formation assay. A. Reagents: - Neutralite Avidin: 20 μg/ml in PBS. - Blocking buffer: 5% BSA, 0.5% Tween 20 in PBS; 1 hour at room temperature. - Assay Buffer: 100 mM KC1, 20 mM HEPES pH 7.6, 1 mM MgCl 2 , 1% glycerol, 0.5% NP-40, 50 mM β-mercaptoethanol, 1 mg/ml BSA, cocktail of protease inhibitors. - ^P T2K protein lOx stock: 10 "8 - 10 ° M "cold" T2K supplemented with 200,000- 250,000 cpm of labeled T2K (Beckman counter). Place in the 4°C microfridge during screening. - Protease inhibitor cocktail (1000X): 10 mg Trypsin Inhibitor (BMB # 109894), 10 mg Aprotinin (BMB # 236624), 25 mg Benzamidine (Sigma # B-6506), 25 mg Leupeptin (BMB # 1017128), 10 mg APMSF (BMB # 917575), and 2mM NaVo 3 (Sigma # S-6508) in 10 ml of PBS. -TRAF2: 10 "7 - 10 5 M biotinylated TRAF2 in PBS. B. Preparation of assay plates: - Coat with 120 μl of stock N-Avidin per well overnight at 4°C. - Wash 2 times with 200 μl PBS. - Block with 150 μl of blocking buffer. - Wash 2 times with 200 μl PBS. C. Assay: - Add 40 μl assay buffer/well. - Add 10 μl compound or extract. - Add 10 μl 33 P-T2K (20-25,000 cpm/0.1-10 pmoles/well =10 '9 - 10 "7 M final cone). - Shake at 25°C for 15 minutes. - Incubate additional 45 minutes at 25 °C. - Add 40 μl biotinylated TRAF2 (0.1-10 pmoles/40 ul in assay buffer) - Incubate 1 hour at room temperature. - Stop the reaction by washing 4 times with 200 μM PBS. - Add 150 μM scintillation cocktail. - Count in Topcount. D. Controls for all assays (located on each plate): a. Non-specific binding b. Soluble (non-biotinylated TRAF2) at 80% inhibition. All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. (1) GENERAL INFORMATION: (I) APPLICANT: Cao , Zhaodan (ii) TITLE OF INVENTION: TRAF2-Associated Kinase (iii) NUMBER OF SEQUENCES: 2 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: SCIENCE & TECHNOLOGY LAW GROUP (B) STREET: 268 BUSH STREET, SUITE 3200 (C) CITY: SAN FRANCISCO (D) STATE: CALIFORNIA (E) COUNTRY: USA (F) ZIP: 94104 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS /MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.30 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US (B) FILING DATE: (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: OSMAN, RICHARD A (B) REGISTRATION NUMBER: 36,627 (C) REFERENCE/DOCKET NUMBER: T97-002 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (415) 343-4341 (B) TELEFAX: (415) 343-4342 (2) INFORMATION FOR SEQ ID NO : 1 : (I) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2994 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 73..2259 (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 1 : GCGGGAGCCC GCCGGCGGTG GCGCGGCGGA GACCCGGCTG GTATAACAAG AGGATTGCCT 60 GATCCAGCCA AG ATG CAG AGC ACT TCT AAT CAT CTG TGG CTT TTA TCT 108 Met Gin Ser Thr Ser Asn His Leu Trp Leu Leu Ser 1 5 10 GAT ATT TTA GGC CAA GGA GCT ACT GCA AAT GTC TTT CGT GGA AGA CAT 156 Asp lie Leu Gly Gin Gly Ala Thr Ala Asn Val Phe Arg Gly Arg His 15 20 25 AAG AAA ACT GGT GAT TTA TTT GCT ATC AAA GTA TTT AAT AAC ATA AGC 204 Lys Lys Thr Gly Asp Leu Phe Ala lie Lys Val Phe Asn Asn lie Ser 30 35 40 TTC CTT CGT CCA GTG GAT GTT CAA ATG AGA GAA TTT GAA GTG TTG AAA 252 Phe Leu Arg Pro Val Asp Val Gin Met Arg Glu Phe Glu Val Leu Lys 45 50 55 60 AAA CTC AAT CAC AAA AAT ATT GTC AAA TTA TTT GCT ATT GAA GAG GAG 300 Lys Leu Asn His Lys Asn lie Val Lys Leu Phe Ala lie Glu Glu Glu 65 70 75 ACA ACA ACA AGA CAT AAA GTA CTT ATT ATG GAA TTT TGT CCA TGT GGG 348 Thr Thr Thr Arg His Lys Val Leu lie Met Glu Phe Cys Pro Cys Gly 80 85 90 AGT TTA TAC ACT GTT TTA GAA GAA CCT TCT AAT GCC TAT GGA CTA CCA 396 Ser Leu Tyr Thr Val Leu Glu Glu Pro Ser Asn Ala Tyr Gly Leu Pro 95 100 105 GAA TCT GAA TTC TTA ATT GTT TTG CGA GAT GTG GTG GGT GGA ATG AAT 444 Glu Ser Glu Phe Leu lie Val Leu Arg Asp Val Val Gly Gly Met Asn 110 115 120 CAT CTA CGA GAG AAT GGT ATA GTG CAC CGT GAT ATC AAG CCA GGA AAT 492 His Leu Arg Glu Asn Gly lie Val His Arg Asp lie Lys Pro Gly Asn 125 " 130 135 140 ATC ATG CGT GTT ATA GGG GAA GAT GGA CAG TCT GTG TAC AAA CTC ACA 540 lie Met Arg Val lie Gly Glu Asp Gly Gin Ser Val Tyr Lys Leu Thr 145 150 155 GAT TTT GGT GCA GCT AGA GAA TTA GAA GAT GAT GAG CAG TTT GTT TCT 588 Asp Phe Gly Ala Ala Arg Glu Leu Glu Asp Asp Glu Gin Phe Val Ser 160 165 170 CTG TAT GGC ACA GAA GAA TAT TTG CAC CCT GAT ATG TAT GAG AGA GCA 636 Leu Tyr Gly Thr Glu Glu Tyr Leu His Pro Asp Met Tyr Glu Arg Ala 175 180 185 GTG CTA AGA AAA GAT CAT CAG AAG AAA TAT GGA GCA ACA GTT GAT CTT 684 Val Leu Arg Lys Asp His Gin Lys Lys Tyr Gly Ala Thr Val Asp Leu 190 195 200 TGG AGC ATT GGG GTA ACA TTT TAC CAT GCA GCT ACT GGA TCA CTG CCA 732 Trp Ser lie Gly Val Thr Phe Tyr His Ala Ala Thr Gly Ser Leu Pro 205 210 215 220 TTT AGA CCC TTT GAA GGG CCT CGT AGG AAT AAA GAA GTG ATG TAT AAA 780 Phe Arg Pro Phe Glu Gly Pro Arg Arg Asn Lys Glu Val Met Tyr Lys 225 230 235 ATA ATT ACA GGA AAG CCT TCT GGT GCA ATA TCT GGA GTA CAG AAA GCA 828 lie lie Thr Gly Lys Pro Ser Gly Ala lie Ser Gly Val Gin Lys Ala 240 245 250 GAA AAT GGA CCA ATT GAC TGG AGT GGA GAC ATG CCT GTT TCT TGC AGT 876 Glu Asn Gly Pro lie Asp Trp Ser Gly Asp Met Pro Val Ser Cys Ser 255 260 265 CTT TCT CGG GGT CTT CAG GTT CTA CTT ACC CCT GTT CTT GCA AAC ATC 924 Leu Ser Arg Gly Leu Gin Val Leu Leu Thr Pro Val Leu Ala Asn lie 270 275 280 CTT GAA GCA GAT CAG GAA AAG TGT TGG GGT TTT GAC CAG TTT TTT GCA 972 Leu Glu Ala Asp Gin Glu Lys Cys Trp Gly Phe Asp Gin Phe Phe Ala 285 290 295 300 GAA ACT AGT GAT ATA CTT CAC CGA ATG GTA ATT CAT GTT TTT TCG CTA 1020 Glu Thr Ser Asp lie Leu His Arg Met Val lie His Val Phe Ser Leu 305 310 315 CAA CAA ATG ACA GCT CAT AAG ATT TAT ATA CAT AGC TAT AAT ACT GCT 1068 Gin Gin Met Thr Ala His Lys lie Tyr lie His Ser Tyr Asn Thr Ala 320 325 330 ACT ATA TTT CAT GAA CTG GTA TAT AAA CAA ACC AAA ATT ATT TCT TCA 1116 Thr lie Phe His Glu Leu Val Tyr Lys Gin Thr Lys lie lie Ser Ser 335 340 345 AAT CAA GAA CTT ATC TAC GAA GGG CGA CGC TTA GTC TTA GAA CCT GGA 1164 Asn Gin Glu Leu lie Tyr Glu Gly Arg Arg Leu Val Leu Glu Pro Gly 350 355 360 AGG CTG GCA CAA CAT TTC CCT AAA ACT ACT GAG GAA AAC CCT ATA TTT 1212 Arg Leu Ala Gin His Phe Pro Lys Thr Thr Glu Glu Asn Pro lie Phe 365 370 375 380 GTA GTA AGC CGG GAA CCT CTG AAT ACC ATA GGA TTA ATA TAT GAA AAA 1260 Val Val Ser Arg Glu Pro Leu Asn Thr lie Gly Leu lie Tyr Glu Lys 385 390 395 ATT TCC CTC CCT AAA GTA CAT CCA CGT TAT GAT TTA GAC GGG GAT GCT 1308 lie Ser Leu Pro Lys Val His Pro Arg Tyr Asp Leu Asp Gly Asp Ala 400 405 410 AGC ATG GCT AAG GCA ATA ACA GGG GTT GTG TGT TAT GCC TGC AGA ATT 1356 Ser Met Ala Lys Ala lie Thr Gly Val Val Cys Tyr Ala Cys Arg lie 415 420 425 GCC AGT ACC TTA CTG CTT TAT CAG GAA TTA ATG CGA AAG GGG ATA CGA 1404 Ala Ser Thr Leu Leu Leu Tyr Gin Glu Leu Met Arg Lys Gly lie Arg 430 435 440 TGG CTG ATT GAA TTA ATT AAA GAT GAT TAC AAT GAA ACT GTT CAC AAA 1452 Trp Leu lie Glu Leu lie Lys Asp Asp Tyr Asn Glu Thr Val His Lys 445 450 455 460 AAG ACA GAA GTT GTG ATC ACA TTG GAT TTC TGT ATC AGA AAC ATT GAA 1500 Lys Thr Glu Val Val lie Thr Leu Asp Phe Cys lie Arg Asn lie Glu 465 470 475 AAA ACT GTG AAA GTA TAT GAA AAG TTG ATG AAG ATC AAC CTG GAA GCG 1548 Lys Thr Val Lys Val Tyr Glu Lys Leu Met Lys lie Asn Leu Glu Ala 480 485 490 GCA GAG TTA GGT GAA ATT TCA GAC ATA CAC ACC AAA TTG TTG AGA CTT 1596 Ala Glu Leu Gly Glu lie Ser Asp lie His Thr Lys Leu Leu Arg Leu 495 500 505 TCC AGT TCT CAG GGA ACA ATA GAA ACC AGT CTT CAG GAT ATC GAC AGC 1644 Ser Ser Ser Gin Gly Thr lie Glu Thr Ser Leu Gin Asp lie Asp Ser 510 515 520 AGA TTA TCT CCA GGT GGA TCA CTG GCA GAC GCA TGG GCA CAT CAA GAA 1692 Arg Leu Ser Pro Gly Gly Ser Leu Ala Asp Ala Trp Ala His Gin Glu 525 530 535 540 GGC ACT CAT CCG AAA GAC AGA AAT GTA GAA AAA CTA CAA GTC CTG TTA 1740 Gly Thr His Pro Lys Asp Arg Asn Val Glu Lys Leu Gin Val Leu Leu 545 550 555 AAT TGC ATG ACA GAG ATT TAC TAT CAG TTC AAA AAA GAC AAA GCA GAA 1788 Asn Cys Met Thr Glu lie Tyr Tyr Gin Phe Lys Lys Asp Lys Ala Glu 560 565 570 CGT AGA TTA GCT TAT AAT GAA GAA CAA ATC CAC AAA TTT GAT AAG CAA 1836 Arg Arg Leu Ala Tyr Asn Glu Glu Gin lie His Lys Phe Asp Lys Gin 575 580 585 AAA CTG TAT TAC CAT GCC ACA AAA GCT ATG ACG CAC TTT ACA GAT GAA 1884 Lys Leu Tyr Tyr His Ala Thr Lys Ala Met Thr His Phe Thr Asp Glu 590 595 600 TGT GTT AAA AAG TAT GAG GCA TTT TTG AAT AAG TCA GAA GAA TGG ATA 1932 Cys Val Lys Lys Tyr Glu Ala Phe Leu Asn Lys Ser Glu Glu Trp lie 605 610 615 620 AGA AAG ATG CTT CAT CTT AGG AAA CAG TTA TTA TCG CTG ACT AAT CAG 1980 Arg Lys Met Leu His Leu Arg Lys Gin Leu Leu Ser Leu Thr Asn Gin 625 630 635 TGT TTT GAT ATT GAA GAA GAA GTA TCA AAA TAT CAA GAA TAT ACT AAT 2028 Cys Phe Asp lie Glu Glu Glu Val Ser Lys Tyr Gin Glu Tyr Thr Asn 640 645 650 GAG TTA CAA GAA ACT CTG CCT CAG AAA ATG TTT ACA GCT TCC AGT GGA 2076 Glu Leu Gin Glu Thr Leu Pro Gin Lys Met Phe Thr Ala Ser Ser Gly 655 660 665 ATC AAA CAT ACC ATG ACC CCA ATT TAT CCA AGT TCT AAC ACA TTA GTA 2124 lie Lys His Thr Met Thr Pro lie Tyr Pro Ser Ser Asn Thr Leu Val 670 675 680 GAA ATG ACT CTT GGT ATG AAG AAA TTA AAG GAA GAG ATG GAA GGG GTG 2172 Glu Met Thr Leu Gly Met Lys Lys Leu Lys Glu Glu Met Glu Gly Val 685 690 695 700 GTT AAA GAA CTT GCT GAA AAT AAC CAC ATT TTA GAA AGG TTT GGC TCT 2220 Val Lys Glu Leu Ala Glu Asn Asn His lie Leu Glu Arg Phe Gly Ser 705 710 715 TTA ACC ATG GAT GGT GGC CTT CGC AAC GTT GAC TGT CTT TAGCTTTCTA 2269 Leu Thr Met Asp Gly Gly Leu Arg Asn Val Asp Cys Leu 720 725 ATAGAAGTTT AAGAAAAGTT TCCGTTTGCA CAAGAAAATA ACGCTTGGGC ATTAAATGAA 2329 TGCCTTTATA GATAGTCACT TGTTTCTACA ATTCAGTATT TGATGTGGTC GTGTAAATAT 2389 GTACAATATT GTAAATACAT AAAAAATATA CAAATTTTTG GCTGCTGTGA AAATGTAATT 2449 TTATCTTTTA ACATTTATAA TTATATGAGG AAATTTGACC TCAGTGATCA CGAGAAGAAA 2509 GCCATGACCG ACCAATATGT TGACATACTG ATCCTCTACT CTGAGTGGGG CTAAATAAGT 2569 TATTTTCTCT GACCGCCTAC TGGAAATATT TTTAAGTGGA ACCAAAATAG GCATCCTTAC 2629 AAATCAGGAA GACTGACTTG ACACGTTTGT AAATGGTAGA ACGGTGGCTA CTGTGAGTGG 2689 GGAGCAGAAC CGCACCACTG TTATACTGGG ATAACAATTT TTTTGAGAAG GATAAAGTGG 2749 CATTATTTTA TTTTACAAGG TGCCCAGATC CCAGTTATCC TTGTATCCAT GTAATTTCAG 2809 ATGAATTATT AAGCAAACAT TTTAAAGTGA ATTCATTATT AAAAACTATT CATTTTTTTC 2869 CTTTGGCCAT AAATGTGTAA TTGTCATTAA AATTCTAAGG TCATTTCAAC TGTTTTAAGC 2929 TGTATTTCTT TAATTCTGCT TACTATTTCA TGGAAAAAAA TAAATTTCTC AATTTTAAAA 2989 AAAAA 2994 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 729 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2 : Met Gin Ser Thr Ser Asn His Leu Trp Leu Leu Ser Asp lie Leu Gly 1 5 10 15 Gin Gly Ala Thr Ala Asn Val Phe Arg Gly Arg His Lys Lys Thr Gly 20 25 30 Asp Leu Phe Ala lie Lys Val Phe Asn Asn lie Ser Phe Leu Arg Pro 35 40 45 Val Asp Val Gin Met Arg Glu Phe Glu Val Leu Lys Lys Leu Asn His 50 55 60 Lys Asn lie Val Lys Leu Phe Ala lie Glu Glu Glu Thr Thr Thr Arg 65 70 75 80 His Lys Val Leu lie Met Glu Phe Cys Pro Cys Gly Ser Leu Tyr Thr 85 90 95 Val Leu Glu Glu Pro Ser Asn Ala Tyr Gly Leu Pro Glu Ser Glu Phe 100 105 110 Leu lie Val Leu Arg Asp Val Val Gly Gly Met Asn His Leu Arg Glu 115 120 125 Asn Gly lie Val His Arg Asp lie Lys Pro Gly Asn lie Met Arg Val 130 135 140 lie Gly Glu Asp Gly Gin Ser Val Tyr Lys Leu Thr Asp Phe Gly Ala 145 150 155 160 Ala Arg Glu Leu Glu Asp Asp Glu Gin Phe Val Ser Leu Tyr Gly Thr 165 170 175 Glu Glu Tyr Leu His Pro Asp Met Tyr Glu Arg Ala Val Leu Arg Lys 180 185 190 Asp His Gin Lys Lys Tyr Gly Ala Thr Val Asp Leu Trp Ser lie Gly 195 200 205 Val Thr Phe Tyr His Ala Ala Thr Gly Ser Leu Pro Phe Arg Pro Phe 210 215 220 Glu Gly Pro Arg Arg Asn Lys Glu Val Met Tyr Lys lie lie Thr Gly 225 230 235 240 Lys Pro Ser Gly Ala lie Ser Gly Val Gin Lys Ala Glu Asn Gly Pro 245 250 255 lie Asp Trp Ser Gly Asp Met Pro Val Ser Cys Ser Leu Ser Arg Gly 260 265 270 Leu Gin Val Leu Leu Thr Pro Val Leu Ala Asn lie Leu Glu Ala Asp 275 280 285 Gin Glu Lys Cys Trp Gly Phe Asp Gin Phe Phe Ala Glu Thr Ser Asp 290 295 300 lie Leu His Arg Met Val lie His Val Phe Ser Leu Gin Gin Met Thr 305 310 315 320 Ala His Lys lie Tyr lie His Ser Tyr Asn Thr Ala Thr lie Phe His 325 330 335 Glu Leu Val Tyr Lys Gin Thr Lys lie lie Ser Ser Asn Gin Glu Leu 340 345 350 lie Tyr Glu Gly Arg Arg Leu Val Leu Glu Pro Gly Arg Leu Ala Gin 355 360 365 His Phe Pro Lys Thr Thr Glu Glu Asn Pro lie Phe Val Val Ser Arg 370 375 380 Glu Pro Leu Asn Thr lie Gly Leu lie Tyr Glu Lys lie Ser Leu Pro 385 390 395 400 Lys Val His Pro Arg Tyr Asp Leu Asp Gly Asp Ala Ser Met Ala Lys 405 410 415 Ala lie Thr Gly Val Val Cys Tyr Ala Cys Arg lie Ala Ser Thr Leu 420 425 430 Leu Leu Tyr Gin Glu Leu Met Arg Lys Gly lie Arg Trp Leu lie Glu 435 440 445 Leu lie Lys Asp Asp Tyr Asn Glu Thr Val His Lys Lys Thr Glu Val 450 455 460 Val lie Thr Leu Asp Phe Cys lie Arg Asn lie Glu Lys Thr Val Lys 465 470 475 480 Val Tyr Glu Lys Leu Met Lys lie Asn Leu Glu Ala Ala Glu Leu Gly 485 490 495 Glu lie Ser Asp lie His Thr Lys Leu Leu Arg Leu Ser Ser Ser Gin 500 505 510 Gly Thr lie Glu Thr Ser Leu Gin Asp lie Asp Ser Arg Leu Ser Pro 515 520 525 Gly Gly Ser Leu Ala Asp Ala Trp Ala His Gin Glu Gly Thr His Pro 530 535 540 Lys Asp Arg Asn Val Glu Lys Leu Gin Val Leu Leu Asn Cys Met Thr 545 550 555 560 Glu lie Tyr Tyr Gin Phe Lys Lys Asp Lys Ala Glu Arg Arg Leu Ala 565 570 575 Tyr Asn Glu Glu Gin lie His Lys Phe Asp Lys Gin Lys Leu Tyr Tyr 580 585 590 His Ala Thr Lys Ala Met Thr His Phe Thr Asp Glu Cys Val Lys Lys 595 600 605 Tyr Glu Ala Phe Leu Asn Lys Ser Glu Glu Trp lie Arg Lys Met Leu 610 615 620 His Leu Arg Lys Gin Leu Leu Ser Leu Thr Asn Gin Cys Phe Asp lie 625 630 635 640 Glu Glu Glu Val Ser Lys Tyr Gin Glu Tyr Thr Asn Glu Leu Gin Glu 645 650 655 Thr Leu Pro Gin Lys Met Phe Thr Ala Ser Ser Gly lie Lys His Thr 660 665 670 Met Thr Pro lie Tyr Pro Ser Ser Asn Thr Leu Val Glu Met Thr Leu 675 680 685 Gly Met Lys Lys Leu Lys Glu Glu Met Glu Gly Val Val Lys Glu Leu 690 695 700 Ala Glu Asn Asn His lie Leu Glu Arg Phe Gly Ser Leu Thr Met Asp 705 710 715 720 Gly Gly Leu Arg Asn Val Asp Cys Leu 725

Claims: WHAT IS CLAIMED IS: 1. An isolated T2K protein comprising SEQ ID NO: 2 or a fragment thereof having T2K- specific activity. 2. An isolated protein according to claim 1 , wherein said protein specifically phosphorylates IκB at serine 36. 3. An isolated protein according to claim 1, wherein said protein comprises a deletion mutant of SEQ ID NO:2, said deletion mutant comprising SEQ ID NO:2, residues 1-250 or 251- 729. 4. A recombinant nucleic acid encoding a protein according to claim 1. 5. A cell comprising a nucleic acid according to claim 4. 6. A method of making an isolated T2K protein, comprising steps: introducing a nucleic acid according to claim 4 into a host cell or cellular extract, incubating said host cell or extract under conditions whereby said nucleic acid is expressed as a transcript and said transcript is expressed as a translation product comprising said protein, and isolating said translation product. 7. An isolated T2K protein made by the method of claim 6. 8. An isolated T2K nucleic acid comprising SEQ ID NO: 1, or a fragment thereof having at least 24 consecutive bases of SEQ ID NO: 1 and sufficient to specifically hybridize with a nucleic acid having the sequence of SEQ ID NO: 1. 9. A method of screening for an agent which modulates the binding of a T2K protein to a binding target, said method comprising the steps of: incubating a mixture comprising: an isolated protein according to claim 1, a binding target of said protein, and a candidate agent; under conditions whereby, but for the presence of said agent, said protein specifically binds said binding target at a reference affinity; detecting the binding affinity of said protein to said binding target to determine an agent- biased affinity, wherein a difference between the agent-biased affinity and the reference affinity indicates that said agent modulates the binding of said protein to said binding target. 10. A method according to claim 9, wherein said binding target is a substrate comprising IκB serine 36 and said binding affinity is detected as phosphorylation of said IκB serine 36. 11. A method of screening for an agent which modulates IκB phosphorylation by an IκB kinase specific for IκB serine 36, said method comprising the steps of: incubating a mixture comprising: an isolated IκB serine 36 specific kinase, a substrate comprising IκB serine 36, and a candidate agent; under conditions whereby, but for the presence of said agent, said kinase specifically phosphorylates said substrate at IκB serine 36 at a reference activity; detecting the phosphorylation of said substrate by said kinase to determine an agent- biased activity, wherein a difference between the agent-biased activity and the reference activity indicates that said agent modulates modulates IκB serine 36 phosphorylation. 12. A method according to claim 11, wherein said kinase comprises the sequence of KIAA0151 or SEQ ID NO: 2, or a fragment of either which specifically phosphorylates IκB at serine 36.

Inventors: CAO ZHAODAN, CAO, ZHAODAN
Applicants: TULARIK INC, TULARIK INC.
Application year: 1998
Main classification: C12N1
IPC codes: A61K38, C07K14, C12N1, C12N5, C12N9, C12N15, C12Q1, G01N33